- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05868083
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
February 21, 2024 updated by: Shanghai Simnova Biotechnology Co.,Ltd.
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of SNC-109 CAR-T Cell Therapy in Subjects With Recurrent Glioblastoma
This is a single arm clinical study to estimate the safety, tolerability and pharmacokinetic (PK) characteristics of Chimeric Antigen Receptor-modified T cells (CAR-T) SNC-109 in patients with recurrent glioblastoma (r-GBM) and preliminarily evaluate the effectiveness, the immunogenicity of the product, as well as their correlation between the changes of cytokines from baseline level after cellular infusion.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
It is planned to recruit about 16 patients with rGBM subjects.
The protocol consists of screening period, Lymphocytes apheresis period, Operation period, pre-infusion evaluation (-2~-1 days), infusion (day 0), infusion observation (day 1-post infusion), and follow-up period (last infusion-720 days).
The incidence of dose limitation toxicity (DLT) will be observed within 28 days after the first infusion.
Subjects in this study will receive multiple infusions, starting with 2×104 CAR+ T cells/dose in the first subject, and the Safety Review Committee (SRC) will evaluate the subsequent dosing regimen, dose, infusion interval, and number of treatment cycles.
Subsequent subjects will be evaluated by the SRC on the basis of available PK and safety data, and the SRC will determine the dosing regimen, dose, infusion interval and number of treatment cycles based on observed evidences.
Study Type
Interventional
Enrollment (Estimated)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Recruiting
- Chinese PLA General Hospital
-
Contact:
- Ling Chen
- Phone Number: 8610-66887329
- Email: chen_ling301@163.com
-
Principal Investigator:
- Ling Chen, MD/PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 and ≤70,both sexes;
- Diagnosed with a history of glioblastoma, and the recurrent glioblastoma has confirmed by histological/molecular pathology (including astrocytoma World Health Organization (WHO) Grade 4);
- Karnofsky (KPS) ≥60;
- The estimated survival time is ≥8 weeks;
- Blood pregnancy tests for women of childbearing age are negative;
- The patient himself/herself, and/or his/her legal guardian, agree to participate in the trial and sign the informed consent form.
Exclusion Criteria:
- Known allergies to study drugs or drugs that may be used in the study;
- Severe concurrent diseases in the heart, lungs, liver, or other vital organs;
- Hypertension is poorly controlled or accompanied by hypertensive crisis or hypertensive encephalopathy;
- In addition to the glioblastoma, with other severe central nervous system diseases or complications or aggressive malignancies;
- Long-term use of immunosuppressant drugs, or large doses of steroids;
- Received live or attenuated vaccine or other surgery had no related to GBM within 4 weeks prior to Lymphocytes apheresis;
- Lymphocytes apheresis or cell infusion combined with infection or unexplained fever.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SNC-109 CAR-T Cells
After the operation and pre-infusion evaluation, SNC-109 CAR-T Cells will be evaluated.
|
SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment related adverse everts
Time Frame: Up to 28 days after first infusion
|
Incidence of adverse events associated with CAR-T cell transfusion within 28 days of the first infusion, abnormal and clinical significant laboratory results
|
Up to 28 days after first infusion
|
Cmax of SNC-109 Cell count
Time Frame: within 2 years after first infusion
|
SNC-109 cell count maximum (Cmax) in peripheral blood (PB) and cerebrospinal fluid (CSF)
|
within 2 years after first infusion
|
Tmax of SNC-109 Cell count
Time Frame: within 2 years after first infusion
|
SNC-109 cell count time to Cmax(Tmax) in peripheral blood (PB) and cerebrospinal fluid (CSF)
|
within 2 years after first infusion
|
AUC of SNC-109 Cell count
Time Frame: within 2 years after first infusion
|
SNC-109 cell count area under the curve (AUC) in peripheral blood (PB) and cerebrospinal fluid (CSF)
|
within 2 years after first infusion
|
Cmax of SNC-109 CAR vector copy number
Time Frame: within 2 years after first infusion
|
SNC-109 CAR vector copy number (VCN) maximum (Cmax) in peripheral blood (PB) and cerebrospinal fluid (CSF)
|
within 2 years after first infusion
|
Tmax of SNC-109 CAR vector copy number
Time Frame: within 2 years after first infusion
|
SNC-109 CAR vector copy number (VCN) time to Cmax(Tmax) in peripheral blood (PB) and cerebrospinal fluid (CSF)
|
within 2 years after first infusion
|
AUC of SNC-109 CAR vector copy number
Time Frame: within 2 years after first infusion
|
SNC-109 CAR vector copy number (VCN) area under the curve (AUC) in peripheral blood (PB) and cerebrospinal fluid (CSF)
|
within 2 years after first infusion
|
Other relevant PK parameters
Time Frame: within 2 years after first infusion
|
Other relevant PK parameters in peripheral blood (PB) and cerebrospinal fluid (CSF)
|
within 2 years after first infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) after infusion
Time Frame: within 2 years after first infusion
|
The data of objective response rate (ORR) after infusion
|
within 2 years after first infusion
|
Progression free survival (PFS) after infusion
Time Frame: within 2 years after first infusion
|
The data of Progression free survival (PFS) after infusion
|
within 2 years after first infusion
|
Overall survival (OS) after infusion
Time Frame: within 2 years after first infusion
|
The data of Overall survival (OS) after infusion
|
within 2 years after first infusion
|
Efficacy assesment for the treatment according to iRANO
Time Frame: within 2 years after first infusion
|
Assessment of disease response rates according to the Immunological Response Assessment in Neuro-Oncology (iRANO)
|
within 2 years after first infusion
|
Changes of Cytokines after infusion
Time Frame: within 2 years after first infusion
|
Changes of cytokines (such as Interleukin-6, Interleukin-8 etc.) in peripheral blood (PB) and cerebrospinal fluid (CSF) pre-and post- infusion and at each of the main follow-up time points, and the time to recovery
|
within 2 years after first infusion
|
Concentration of Human anti-chimeric antibody (HACA)
Time Frame: within 2 years after first infusion
|
Detection of changes in peripheral blood and cerebrospinal fluid Human anti-chimeric antibody (HACA)
|
within 2 years after first infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 24, 2022
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
April 18, 2023
First Submitted That Met QC Criteria
May 11, 2023
First Posted (Actual)
May 22, 2023
Study Record Updates
Last Update Posted (Estimated)
February 23, 2024
Last Update Submitted That Met QC Criteria
February 21, 2024
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNC-109-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioblastoma Multiforme
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Active, not recruitingRecurrent Glioblastoma Multiforme | Progressive Glioblastoma Multiforme | Anaplastic Astrocytoma or GliosarcomaUnited States
-
WPD Pharmaceuticals Sp. z o.o.National Center for Research and Development, Poland; Worldwide Clinical TrialsRecruitingRecurrent Glioblastoma MultiformePoland
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
Sun Yat-sen UniversityUnknown
-
Novartis PharmaceuticalsCompletedRecurrent Glioblastoma MultiformeUnited States, Belgium, Australia, Spain, France, Canada
-
CASI Pharmaceuticals, Inc.CompletedRecurrent Glioblastoma MultiformeUnited States
-
Accendatech USA Inc.Avance Clinical Pty Ltd.; C3 Research AssociatesRecruitingRecurrent Glioblastoma Multiforme(GBM)United States
-
NovartisTerminatedRecurrent Glioblastoma Multiforme (GBM)United States
-
University Hospital FreiburgUniversity of Freiburg; Clinical Trials Center Freiburg; AG-NUK-RTUnknownRecurrent Glioma (Glioblastoma Multiforme)Germany
Clinical Trials on SNC-109 CAR-T Cells
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingInfectious Diseases | Hematological MalignanciesChina